Replies to post #582 on ImmunoGen Inc (IMGN)

[skitahoe]

I think you're right, and it could do better than that if at ASCO they commit to filing a BLA for IMGN853 before the end of the year after conferring with the FDA.

I believe it was the FDA who insisted in having the weakest patients in this trial, not who IMGN originally wanted to target, clearly that caused the failure. If they look at the subsets which would have gained approval it's clear that the drug is achieving acceptable benefits, and survival data appears to improve with time, even if progression is noted. Is the progression actually pseudoprogression, i.e. the tumor essentially necrotic mass, that may need to be determined.

In short, I believe if the company clearly demonstrates that approval should happen during the first half of 2020, the stock will achieve new 52 week highs before the years end.

Gary